ROMA软件系统在卵巢癌患者的临床应用价值研究

详细信息    查看全文 | 推荐本文 |

英文篇名：Clinical application value of ROMA software system in ovarian cancer patients 作者：陈倩岚 ; 梁景娥 ; 黄雪珍 英文作者：Chen Qinglan;Liang Jinge;Huang Xuezhen; 关键词：卵巢癌 ; 预后 ; ROMA软件系统 ; HE4 ; CA125 英文关键词：Ovarian cancer;;The prognosis;;ROMA software system;;HE4;;CA125 中文刊名：ZYLY 英文刊名：Clinical Journal of Chinese Medicine 机构：南方医科大学附属小榄医院; 出版日期：2019-01-25 出版单位：中医临床研究 年：2019 期：v.11 基金：项目名称:ROMA软件系统在卵巢癌患者的临床应用价值研究,编号:003603A020218035 语种：中文; 页：ZYLY201903046 页数：3 CN：03 ISSN：11-5895/R 分类号：94-96

摘要

目的:ROMA软件系统在卵巢癌患者的临床应用价值。方法:纳入我院卵巢癌患者的病例样本共计3685例,其中有96例证实为卵巢癌样本,采用全自动化学发光免疫法对肿瘤组织CA125、HE4的相对表达量进行检测,并采用ROMA软件系统计算ROMA值,对卵巢癌的发生风险是否具有相关性。结果:96例卵巢癌组织的CA125、HE4的相对表达量、ROMA值分别为1.036,1.532,10.135,95%CI为0.323～0.534,0.369～0.547,0.412～0.632。CA125、HE4表达、ROMA值与年龄、瘤组织大小无相关性(P> 0.05);而淋巴受累、肿瘤分期、分化程度、肿瘤侵袭深度、是否转移等方面,HE4、CA125相对表达量、ROMA值的上升(P <0.05),HE4,CA125的表达和ROMA值的升高与淋巴结转移,肿瘤分期,分化程度,肿瘤浸润深度以及转移风险是否相关有关。Logistic回归分析用于分析CA125和HE4的相对表达水平,ROMA值和临床病例因素。HE4和CA125的相对表达与ROMA值之间的相关性增加了淋巴结转移的风险。调整后的风险为OR=5.05,95%CI为1.14-23.45,P=0.004。结论:ROMA值与卵巢癌发生发展有一定的相关性,ROMA软件系统有助于卵巢癌筛查及预测。
        Objective: To investigate the clinical application value of ROMA software system in ovarian cancer patients. Methods:A total of 3,685 cases were included in the samples of ovarian cancer patients in our hospital, among which 96 cases were actually ovarian cancer samples. The relative expression levels of CA125 and HE4 in tumor tissues were tested by automatic chemiluminescence immunoassay, and the ROMA software system was used to calculate the ROMA value. Results: The relative expression of CA125 and HE4 and ROMA in 96 ovarian cancer patients were 1.036, 1.532, 10.135, 95%CI 0.323-0.534, 0.369-0.547, 0.412-0.632, respectively. CA125,HE4 expression and ROMA values were not correlated with age and tumor tissue size(P>0.05). In terms of lymphatic involvement, tumor stage, differentiation degree, tumor invasion depth and metastasis, the relative expression of HE4 and CA125 and the increase of ROMA value(P<0.05) were correlated with lymph node metastasis, tumor stage, differentiation degree, tumor invasion depth and metastasis risk.Logistic regression analysis was used to analyze the relative expression levels, ROMA values and clinical case factors of CA125 and HE4.The correlation between the relative expression of HE4 and CA125 and the ROMA values increased the risk of lymph node metastasis.The adjusted risk was OR=5.05, 95%CI 1.14-23.45, P=0.004. Conclusion: There was a correlation between the ROMA value and the development of ovarian cancer. The ROMA software system could help screen and predict ovarian cancer.

引文

[1]中华医学会检验分会,卫生部临床检验中心,中华检验医学杂志编辑委员会,等.肿瘤标志物的临床应用建议[J].中华检验医学杂志,2012,35(02):103-116.
    [2]闫先侠,孙晓,等.血清人附睾蛋白4联合CA125检测在卵巢癌诊断中的应用[J].现代检验医学杂志,2015,30(01):134-136.
    [3]Azzam AZ,Hashad DI,Kamel NAF,et al.Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma:is it time for a step forward?[J].Arch Gynecol Obstet,2013,288(01):167-172.
    [4]黄斌.HE4联合CA125对早期卵巢癌的诊断价值研究[J].实用癌症杂志,2016,31(05):720-722.
    [5]王慜杰,齐军,王海,等.人附睾蛋白4与糖类抗原125联合检测在卵巢癌诊断中的应用价值[J].中华肿瘤杂志,2011,33(07):540-543.
    [6]雷震山,高鹏,吴金斌.联合检测血清HE4和CA125对卵巢癌患者的临床诊断价值探讨[J].国际检验医学杂志,2016,37(04):544-546.
    [7]张碧莲.HE4和CA125的联合检测对卵巢癌的早期诊断与鉴别诊断的临床意义[J].实验与检验医学,2015(05):659-661.